Form 8-K - Current report:
SEC Accession No. 0001193125-25-073987
Filing Date
2025-04-07
Accepted
2025-04-07 08:00:49
Documents
15
Period of Report
2025-04-04
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d905141d8k.htm   iXBRL 8-K 28838
2 EX-3.1 d905141dex31.htm EX-3.1 10332
  Complete submission text file 0001193125-25-073987.txt   201565

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20250404.xsd EX-101.SCH 3882
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20250404_def.xml EX-101.DEF 13697
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20250404_lab.xml EX-101.LAB 22681
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20250404_pre.xml EX-101.PRE 14665
18 EXTRACTED XBRL INSTANCE DOCUMENT d905141d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 25816392
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)